Search

Susan C Schiavi

from Hopkinton, MA
Age ~66
Get Report
Also known as:
Susan Stlaurent, Susan C Schiav, Susan Schiari
Phone and address:
48 Wedgewood Dr, Hopkinton, MA 01748
Related to:
Evan CopelandNicholas Stlaurent, 67Nicholas Stlaurent, 30Amanda Stlaurent, 31Nicholas SchiaviNicholas S Laurent, 30
Connected to:
Christopher T Schiavino, 37Reinaldo J Schiavinato, 50Sara J Schiavi, 35Aleen C Schiavo, 41Ashley E Schiavone, 41Brenda F Schiavoni, 60George G Schiavo, 48Gregg Schiavoni, 55Holly K Schiavone, 59Isabella R Schiavone, 99

Susan Schiavi Phones & Addresses

  • 48 Wedgewood Dr, Hopkinton, MA 01748
  • Worcester, MA
  • Fayville, MA

Resumes

Resumes

Susan Schiavi Photo 1

Chief Scientific Officer

View page
Location:
48 Wedgewood Dr, Hopkinton, MA 01748
Industry:
Biotechnology
Work:
Precithera
Chief Scientific Officer
Sanofi Genzyme Jan 2005 - Dec 2014
Senior Scientific Director, Tissue Protection and Repair
Sanofi Genzyme Jan 1998 - Jan 2005
Senior and Principal Scientist
Sanofi Genzyme Jan 1993 - Jan 1997
Staff Scientist I and Ii
Education:
Harvard Medical School 1988 - 1992
University of Massachusetts Medical School 1982 - 1988
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Biotechnology
Pharmaceutical Industry
Life Sciences
Drug Development
Molecular Biology
Science
Clinical Research
Drug Discovery
Biopharmaceuticals
Cell Culture
Fda
Endocrinology
Strategy
Immunology
Assay Development
Bioinformatics
Lifesciences
Susan Schiavi Photo 2

Susan Schiavi

View page

Publications

Us Patents

Phosphatonin-Related Gene And Methods Of Use Thereof

View page
US Patent:
20020115627, Aug 22, 2002
Filed:
Jul 19, 2001
Appl. No.:
09/909775
Inventors:
Susan Schiavi - Hopkinton MA, US
Stephen Madden - Sudbury MA, US
Parthasarathy Manavalan - Medway MA, US
Michael Levine - Owings Mills MD, US
Suzanne de Beur - Baltimore MD, US
International Classification:
A61K048/00
C12Q001/00
C12Q001/68
US Classification:
514/044000, 435/006000, 435/004000
Abstract:
This invention provides methods for modulating phosphate homeostasis and renal phosphate transport by delivering agents that alter the expression of the FRP-4 gene or alter the activity of the FRP-4 protein. The methods of the invention are useful for modulating bone mineralization, renal phosphate transport, alleviating oncogenic osteomalacia-associated symptoms and treating phosphate homeostasis-related disease. The invention further provides methods for reducing phosphate re-absorption by delivering to a subject FRP-4 protein or polynucleotides that encode this protein. In addition, the invention provides methods for detecting and monitoring expression of the FRP-4 gene and modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia. Finally, the invention provides methods for screening candidate agents to identify compositions that modify the activity of the FRP-4 gene and protein.

Tgf-Ss Receptor Fusion Proteins And Other Tgf-Ss Antagonists For Reducing Tgf-Ss Signaling

View page
US Patent:
20190248881, Aug 15, 2019
Filed:
Dec 4, 2018
Appl. No.:
16/209889
Inventors:
- Montreal, CA
Susan SCHIAVI - Hopkinton MA, US
International Classification:
C07K 16/22
A61K 47/54
A61P 19/08
A61K 47/65
C07K 14/495
Abstract:
The present invention provides TGF-β antagonists and conjugates thereof, as well as methods of using such compositions for attenuating TGF-β signaling. These novel compositions and methods may be useful for treating individuals suffering from devastating diseases associated with elevated TGF-β signaling, including skeletal disorders, such as osteogenesis imperfecta (OI), and muscular diseases, such as muscular dystrophies.

Tgf-Beta Antagonist Conjugates

View page
US Patent:
20190216943, Jul 18, 2019
Filed:
Aug 11, 2017
Appl. No.:
16/324501
Inventors:
- Montreal, CA
Susan SCHIAVI - Hopkinton MA, US
International Classification:
A61K 47/68
A61K 9/00
A61P 19/08
A61K 31/4439
A61K 47/64
Abstract:
The present invention provides conjugates containing a (i) TGF-β antagonist, such as a TGF-β antagonist antibody, protein, peptide, or small molecule capable of inhibiting TGF-β signaling, bound to (ii) a bone-targeting moiety. The bone targeting moiety localizes the TGF-β antagonist to osseous tissue. The conjugates described herein provide a therapeutic paradigm for the treatment of various diseases associated with elevated TGF-β signaling and elevated bone turnover, such as osteogenesis imperfecta and other bone pathologies.
Control profile
Susan C Schiavi from Hopkinton, MA, age ~66 Get Report